Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Letter to the Editor

Inflammation and LDL Reduction

Author(s): Vasilios Gabriel Athyros*, George Sfikas and Charalambos Koumaras

Volume 21, Issue 1, 2023

Published on: 13 October, 2022

Page: [69 - 70] Pages: 2

DOI: 10.2174/1570161120666221004150503

conference banner
« Previous Next »
[1]
García RD, Asensio JA, Perdicaro DJ, De Los Ángeles PM. The role of inflammation as a preponderant risk factor in cardiovascular diseases. Curr Vasc Pharmacol 2022; 20(3): 244-59.
[http://dx.doi.org/10.2174/1570161120666220201160038] [PMID: 35105294]
[2]
Athyros V, Kakafika A, Tziomalos K, Karagiannis A, Mikhailidis D. Pleiotropic effects of statins--Clinical evidence. Curr Pharm Des 2009; 15(5): 479-89.
[http://dx.doi.org/10.2174/138161209787315729] [PMID: 19199976]
[3]
Wang X, Lin Y, Luo N, et al. Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits. Chin Med J 2014; 127(16): 2953-9.
[PMID: 25131234]
[4]
Di Sciascio G. The ARMYDA trials (Atorvastatin for reduction of myocardial damage during angioplasty) at campus Bio-Medico University: Rationale, results and future horizons. Fundam Clin Pharmacol 2007; 21 (Suppl. 2): 41-3.
[http://dx.doi.org/10.1111/j.1472-8206.2007.00539.x] [PMID: 18001321]
[5]
Gao Y, Jia ZM, Sun YJ, Zhang ZH, Ren LN, Qi GX. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2012; 125(13): 2250-4.
[PMID: 22882843]
[6]
Slhessarenko JR, Hirata M, Sousa A, et al. Effect of preloading with high dose of rosuvastatin on serum levels of inflammatory markers after percutaneous coronary intervention. J Invasive Cardiol 2020; 32(9): 335-41.
[PMID: 32568096]
[7]
Yang J, Liu C, Zhang L, et al. Intensive atorvastatin therapy attenuates the inflammatory responses in monocytes of patients with unstable angina undergoing percutaneous coronary intervention via peroxisome proliferator-Activated receptor γ activation. Inflammation 2015; 38(4): 1415-23.
[http://dx.doi.org/10.1007/s10753-015-0116-2] [PMID: 25604313]
[8]
Katsiki N, Triposkiadis F, Giannoukas AD, Mikhailidis DP. Statin loading in cardiovascular surgery. Curr Opin Cardiol 2018; 33(4): 436-43.
[http://dx.doi.org/10.1097/HCO.0000000000000519] [PMID: 29601328]
[9]
Zhou X, Dai J, Xu X, et al. Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: A network meta-analysis. Angiology 2019; 70(4): 305-16.
[http://dx.doi.org/10.1177/0003319718801246] [PMID: 30261736]
[10]
Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: A post-hoc analysis. Lancet 2010; 376(9756): 1916-22.
[http://dx.doi.org/10.1016/S0140-6736(10)61272-X] [PMID: 21109302]
[11]
Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168(4): 3846-52.
[http://dx.doi.org/10.1016/j.ijcard.2013.06.024] [PMID: 24001698]
[12]
Kargiotis K, Katsiki N, Athyros V, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014; 12(3): 505-11.
[http://dx.doi.org/10.2174/15701611113119990009] [PMID: 24805248]

Rights & Permissions Print Cite
Article Metrics
25
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy